This venture capital firm invests in pre-seed to seed stage opportunities with initial check sizes ranging from $500k to $1M and maintains reserves for follow-on capital. While the firm prefers to lead deals, it is open to syndication. Investment geography spans both Europe and the United States.
The investment team has a deep technical background in software, artificial intelligence, and algorithms. Within life sciences and healthcare, the firm is focused on techbio, synthetic biology, computational biology, chemistry & materials.
The firm is also open to hardware (e.g., diagnostics or medical devices) that enable novel data modalities, digital health, and therapeutic platforms.
However, the firm does not invest in traditional therapeutic assets and is indication-agnostic. Opportunities can be considered as early as the pre-prototype stage, provided there is a roadmap toward intellectual property or patent protection.
There are no strict team or company prerequisites, though the firm has a preference for technical founders with strong scientific grounding. The firm may take a board or observer seat depending on the opportunity.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment